Sandoz Group AG (SDZ)
SIX Swiss Exchange · Switzerland · prices in CHF · close of 27 Oct 2026
Key indicators
| Last close | CHF 82.10 |
|---|---|
| 52-week range | 48.15 – 83.38 |
| Return, 1 month / 3 months | +15.4% / +29.3% |
| Return, 1 year / 3 years | +65.7% / +252.0% |
| Trend | Uptrend |
| RSI (14) | 78 |
| Volatility (1 year) | 29.5% |
| Worst drawdown (1 year) | -17.6% |
| Average daily value traded | 93.00M CHF |
| Dividend yield | 1.0% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Sandoz Group is a pharmaceutical company based in Switzerland that develops and makes generic medicines and biosimilars, which are lower-cost versions of established drugs. It supplies these products to healthcare providers, pharmacies and patients across many countries, covering a broad range of therapeutic areas. The business also produces active pharmaceutical ingredients and offers other pharmaceutical services, positioning it as a supplier of affordable medicines rather than original branded treatments.
Sandoz Group AG trades under the code SDZ on the SIX Swiss Exchange in Switzerland, with its price quoted in Swiss francs (CHF). Our dividend records, which start in 2019, show payments in 3 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Sandoz Group AG (SDZ) trades on the SIX Swiss Exchange in Switzerland. It last closed at CHF 82.10 on 27 October 2026.
Its price-based Market X-Ray is 74 out of 100 (a strong price profile), ranking 15 of 226 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 65.7% and over the last three months it rose 29.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on SIX Swiss Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 86 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 22.8% | ||
| From 52-week high | -0.3% | ||
| Momentum | 88 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 29.3% | ||
| 6-month return | 30.6% | ||
| 12-month return, skipping the last month | 43.6% | ||
| Stability (higher is calmer) | 62 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 29.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -17.6% | ||
| Liquidity | 96 · Strong | Trades actively. | |
| Average daily value traded | 93.00M CHF | ||
| Zero-volume days | 0.0% | ||
| Income | 9 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.0% | ||
| Years with dividends | 3 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +6.5% |
|---|---|
| 1 month | +15.4% |
| 3 months | +29.3% |
| 6 months | +30.6% |
| 1 year | +65.7% |
| 3 years | +252.0% |
| 5 years | – |
Signals
| 50-day / 200-day average | 71.49 / 66.84 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.09 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 13 Apr 2026 | CHF 0.8000 |
| 17 Apr 2025 | CHF 0.6000 |
| 3 May 2024 | CHF 0.4500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on SIX Swiss Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.